Ikena Oncology Inc expected to post a loss of 43 cents a share - Earnings Preview

ImageneBio

08/03/2024 12:32

* Ikena Oncology Inc  IKNA.OQ   IKNA.O  is expected to show
a fall
in quarterly revenue when it reports  results on March 12
(estimated) for the period ending December 31 2023
    * The Boston Massachusetts-based  company is expected to
report a
42.4% decrease in revenue to $3.137 million from $5.45 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Ikena Oncology Inc is
for a
loss of 43 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ikena
Oncology
Inc is $8.00​, above​ its last closing price of $1.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.42       -0.43      -0.40     Beat    7
 Jun. 30 2023  -0.46       -0.47      -0.44     Beat    7.3
 Mar. 31 2023  -0.47       -0.47      -0.39     Beat    16.6​
 Dec. 31 2022  -0.53       -0.48      -0.40     Beat    16.1
 ​​Sep.        -0.48       -0.50      -0.48     Beat    3.1
 30 2022                                                
 Jun. 30 2022  -0.47       -0.49      -0.57     Missed  -16.8​
 Mar. 31 2022  -0.40       -0.42      -0.47     Missed  -12.4
 Dec. 31 2021  -0.57       -0.51      0.07      Beat    113.7
 This summary was machine generated March 8 at 12:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)